ASCO GU Conference Coverage
Filter News By:
Featured News
View all
More News
(PMLiVE.com [UK]) Feb 17, 2020 - Bristol-Myers Squibb has unveiled long-term results for Opdivo in renal cell carcinoma, which demonstrated efficacy with and without CTLA4 blocker Yervoy.
(Medscape Medical News) Feb 14, 2020 - Practice-changing studies in cancer care are almost always the result of an improvement in efficacy that "moves the needle," usually in terms of progression-free or overall survival. But here at...
(Medscape Medical News) Feb 17, 2020 - It seemed like a sensible measure for desperate times, but reducing the standard frequency of doses of bacille Calmette-Guérin (BCG; Merck) for the treatment of high-grade bladder cancer resulted in...
(MedPage Today) Feb 15, 2020 - Patients with cisplatin-ineligible advanced bladder cancer achieved durable objective responses with the combination of pembrolizumab (Keytruda) and a newly approved antibody-drug conjugate (ADC), new data...
(MedPage Today) Feb 17, 2020 - Pairing immunotherapy with stereotactic body radiation therapy (SBRT) produced mixed results in advanced renal cell carcinoma (RCC) in two preliminary trials reported here.
(MedPage Today) Feb 14, 2020 - Immediate treatment of limited metastatic recurrence of prostate cancer led to a fourfold improvement in the proportion of patients alive without androgen deprivation therapy (ADT) at 5 years, according to...
(MedPage Today) Feb 14, 2020 - More than a fourth of men with high-risk prostate cancer had lymph node or distant metastases missed by CT or MRI but detected by PET imaging targeting prostate specific membrane antigen (PSMA), a...
(Yahoo! Finance) Feb 15, 2020 - Mirati Therapeutics, Inc., a clinical stage targeted oncology company, today announced the presentation of initial data from an ongoing investigator sponsored Phase 1/2 clinical trial of sitravatinib in...
(Decipher) Feb 13, 2020 - Decipher Biosciences today announced that a Decipher GRID molecular subtyping signature, studied in patients from the phase III, randomized controlled trial, CHAARTED, successfully predicted which prostate cancer...
(Dana-Farber) Feb 15, 2020 - Scientists report promising activity of a novel drug that targets a key molecular driver of clear cell renal cell carcinoma (ccRCC) in patients with metastatic disease. Researchers from Dana-Farber Cancer...

OBR Tweets

Apr 16
Early Impressions of IMpower010: What Might This Mean for Immunotherapy in Early-Stage Non-Small Cell Lung Cancer?… https://t.co/MwVpuqeCFN

Dec 06
Stephen Ansell, MD, PhD, of @MayoCancerCare on options for lymphoma patients who are refractory to CAR T-cell treat… https://t.co/0in19JpTFM

Dec 06
@TomBmt133 of @UCSFCancer considers the significance of the IKEMA study #ASH20 https://t.co/hPGQ0EeLgx

Dec 06
@MichaelDJain on immunotherapy treatment trends in the management of aggressive lymphomas @MoffittNews #ASH20 https://t.co/9XpyqMU0X3

Dec 06
Bhavana Bhatnagar, DO, regarding data on racial disparities in the treatment of AML from #ASH20 https://t.co/IWQOcPAupf

Sep 24
Cristina Suárez, MD, of @vallhebron offers opinion on whether the CheckMate 9ER trial is practice-changing #ESMO20 https://t.co/6m8UCjJPxE

Sep 24
Andrew Schmidt, MD, @dr_aschmidt of @DanaFarber regarding the COVID-19 and Cancer Outcomes Study (CCOS) presented a… https://t.co/tbmT0twPFA

Sep 24
Erika Hamilton, MD, @ErikaHamilton9 of @SarahCannonDocs regarding the Phase III monarchE trial presented at #ESMO20 https://t.co/AiqtvpEZ7u

Sep 24
Giuseppe Giaccone, PhD, MD, of @WeillCornell regarding the step 1 results of the Phase III ATALANTE-1 trial in NSCL… https://t.co/D5Su3qEkbb

Sep 24
Pasi A. Jänne, MD, PhD, of @DanaFarber shares data from #ESMO20 investigating mobocertinib https://t.co/idTloLVyBj